title: [Lisinopril-induced changes in antioxidant defense in patients with acute coronary syndrome and concomitant diabetes mellitus type 2].
abstract: OBJECTIVE
  To examine antioxidant defense (AOD) in patients with acute coronary syndrome (ACS) and concominant diabetes mellitus type 2 (DM2) as well as AOD changes related to lisinopril administration.
  
  
  METHODS
  AOD was studied for a year (by activity of glutathion reductase and myeloperoxidase of neutrophils, catalase and superoxide dismutase of blood) in 94 patients with ACS (35 of them had DM2).
  
  
  RESULTS
  The number of recurrent coronary events for a year was significantly more in patients with ACS and DM. Such patients had initially lower activity of catalase, higher blood glucose, circulating immune complexes, creatinine, urinary protein. The lowest catalase activity was in DM patients who had recurrent infarction or died. Low catalse activity was accompanied with the highest blood creatinine and protein, more severe systolic dysfunction of the left ventricle. Compared to captopril, administration of lisinopril in hospital increased catalase activity, lowered blood creatinine, eliminated protein in the urine. These changes were associated with a significantfall in the number of cases with progressive chronic cardiac failure and lethal outcomes.
authors.forename: A E
authors.initials: AE
authors.lastname: Kratnov
authors.forename: S A
authors.initials: SA
authors.lastname: Popov
authors.forename: A A
authors.initials: AA
authors.lastname: Kratnov
authors.forename: Iu O
authors.initials: IuO
authors.lastname: Dem'iankova
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002216:Captopril / Q000627:therapeutic use; D002374:Catalase / Q000097:blood / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005980:Glutathione Reductase / Q000097:blood / Q000187:drug effects; D006801:Humans; D017706:Lisinopril / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D009504:Neutrophils / Q000201:enzymology; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D010088:Oxidoreductases / Q000097:blood* / Q000187:drug effects; D009195:Peroxidase / Q000097:blood / Q000187:drug effects; D012720:Severity of Illness Index; D013053:Spectrophotometry; D013482:Superoxide Dismutase / Q000097:blood / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D002216:Captopril; D017706:Lisinopril; D010088:Oxidoreductases; D002374:Catalase; D009195:Peroxidase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase